Literature DB >> 21631600

Capsular serotype of Staphylococcus aureus in the era of community-acquired MRSA.

Deena E Sutter1, Amy M Summers, Christine E Keys, Kimberly L Taylor, Carl E Frasch, LoRanee E Braun, Ali I Fattom, Margaret C Bash.   

Abstract

Capsular polysaccharide (CP) plays an important role in the pathogenicity and immunogenicity of Staphylococcus aureus, yet the common serotypes of S. aureus isolated from US pediatric patients have not been reported. We investigated capsular serotype as well as methicillin susceptibility, presence of Panton-Valentine leukocidin (PVL), and clonal relatedness of pediatric S. aureus isolates. Clinical isolates were tested for methicillin susceptibility, presence of mecA, lukS-PV and lukF-PV, cap5 and cap8 genes by PCR, and for capsular or surface polysaccharide expression (CP5, CP8, or 336 polysaccharide) by agglutination. Genetic relatedness was determined by pulsed-field gel electrophoresis. All S. aureus isolates encoded cap5 or cap8. Sixty-nine percent of 2004-2005 isolates were methicillin-susceptible (MSSA) and most expressed a detectable capsule. The majority of MRSA isolates (82%) were unencapsulated, exposing an expressed cell wall techoic acid antigen 336. Pulsed-field type USA300 were MRSA, PVL-positive, unencapsulated strains that were associated with deep skin infections and recurrent disease. Over half (58%) of all isolates from invasive pediatric dermatologic infections were USA300. All pediatric isolates contained either capsule type 5 or capsule type 8 genes, and roughly half of the S. aureus clinical disease isolates from our population were diverse MSSA-encapsulated strains. The majority of the remaining pediatric clinical disease isolates were unencapsulated serotype 336 strains of the PVL(+) USA300 community-associated-MRSA clone. FEMS Immunology & Medical Microbiology
© 2011 Federation of European Microbiological Societies. Published by Blackwell Publishing Ltd. No claim to original US government works.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21631600     DOI: 10.1111/j.1574-695X.2011.00822.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  17 in total

1.  Rapid and reliable identification of Staphylococcus aureus capsular serotypes by means of artificial neural network-assisted Fourier transform infrared spectroscopy.

Authors:  Tom Grunert; Mareike Wenning; María Sol Barbagelata; Martina Fricker; Daniel O Sordelli; Fernanda R Buzzola; Monika Ehling-Schulz
Journal:  J Clin Microbiol       Date:  2013-05-08       Impact factor: 5.948

Review 2.  Mouse models for infectious diseases caused by Staphylococcus aureus.

Authors:  Hwan Keun Kim; Dominique Missiakas; Olaf Schneewind
Journal:  J Immunol Methods       Date:  2014-04-24       Impact factor: 2.303

3.  Evaluation of serotypes 5 and 8 capsular polysaccharides in protection against Staphylococcus aureus in murine models of infection.

Authors:  Brian L Cheng; Travis B Nielsen; Paul Pantapalangkoor; Fan Zhao; Jean C Lee; Christopher P Montgomery; Brian Luna; Brad Spellberg; Robert S Daum
Journal:  Hum Vaccin Immunother       Date:  2017-04-19       Impact factor: 3.452

Review 4.  Will there ever be a universal Staphylococcus aureus vaccine?

Authors:  Gerald B Pier
Journal:  Hum Vaccin Immunother       Date:  2013-06-21       Impact factor: 3.452

Review 5.  Development of a vaccine against Staphylococcus aureus.

Authors:  Brad Spellberg; Robert Daum
Journal:  Semin Immunopathol       Date:  2011-11-14       Impact factor: 9.623

Review 6.  Prevention and treatment of Staphylococcus aureus biofilms.

Authors:  Mohini Bhattacharya; Daniel J Wozniak; Paul Stoodley; Luanne Hall-Stoodley
Journal:  Expert Rev Anti Infect Ther       Date:  2015-11-13       Impact factor: 5.091

7.  Efficacy profile of a bivalent Staphylococcus aureus glycoconjugated vaccine in adults on hemodialysis: Phase III randomized study.

Authors:  Ali Fattom; Albert Matalon; John Buerkert; Kimberly Taylor; Silvia Damaso; Dominique Boutriau
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

8.  USA300 and USA500 clonal lineages of Staphylococcus aureus do not produce a capsular polysaccharide due to conserved mutations in the cap5 locus.

Authors:  Susan Boyle-Vavra; Xue Li; Md Tauqeer Alam; Timothy D Read; Julia Sieth; Colette Cywes-Bentley; Ginette Dobbins; Michael Z David; Neha Kumar; Samantha J Eells; Loren G Miller; David J Boxrud; Henry F Chambers; Ruth Lynfield; Jean C Lee; Robert S Daum
Journal:  MBio       Date:  2015-04-07       Impact factor: 7.867

Review 9.  Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors.

Authors:  Annaliesa S Anderson; Alita A Miller; Robert G K Donald; Ingrid L Scully; Jasdeep S Nanra; David Cooper; Kathrin U Jansen
Journal:  Hum Vaccin Immunother       Date:  2012-08-24       Impact factor: 3.452

10.  The comparison of Staphylococcus aureus types 5 and 8 with respect to methicillin resistance in patients admitted to Al-Zahra Hospital by PCR.

Authors:  Seyed Asghar Havaei; Sharareh Moghim; Ali Mohamadi Bardebari; Tahmineh Narimani; Amir Azimian; Mojtaba Akbari
Journal:  Adv Biomed Res       Date:  2013-03-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.